Physician profile
Andrew Berman
NPI 1427172709
$3,645.35
in general payments reported to CMS, 2019-2025
25 companies · $509 in 2025
The $509 reported for 2025 was more than what 75% of Plastic Surgery Within The Head & Neck providers received nationally (typical 2025 total: $238).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $388 · 2021: $447 · 2022: $799 · 2023: $803 · 2024: $479 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,790.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $989.44 | 2020-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $438.07 | 2022-2025 | |
| Genzyme Corporation | $309.47 | 2019-2025 | |
| Amgen INC. | $222.39 | 2022-2025 | Tezspire |
| Optinose US, INC. | $212.86 | 2019-2023 | |
| Hikma Pharmaceuticals USA | $198.74 | 2023-2025 | Ryaltris |
| Incyte Corporation | $196.66 | 2022-2023 | Opzelura |
| Octapharma USA, INC. | $178.97 | 2019-2024 | Cutaquig, Panzyga |
| Merz North America, INC. | $142.45 | 2020-2025 | Xeomin |
| Glaxosmithkline, LLC. | $99.65 | 2020-2023 | Nucala, Trelegy Ellipta |
| Stryker Corporation | $82.05 | 2022-2024 | Xpress Loprofile |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.02 | 2020-2021 | |
| Eyevance Pharmaceuticals LLC | $74.84 | 2020-2021 | |
| Genentech USA, INC. | $74.83 | 2024-2025 | Xolair |
| Astrazeneca Pharmaceuticals LP | $64.20 | 2019-2024 | Tezspire |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $45.73 | 2021 | |
| Lilly USA, LLC | $34.51 | 2024 | Ebglyss, Taltz |
| Takeda Pharmaceuticals U.S.A., INC. | $34.41 | 2020 | |
| Phadia US INC. | $33.14 | 2021-2024 | Immunocap |
| Biocryst Pharmaceuticals, INC. | $30.20 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $25.94 | 2021 | |
| Circassia INC. | $22.97 | 2019 | |
| Shire North American Group INC | $21.87 | 2019 | |
| Masimo Corporation | $16.99 | 2021 | |
| Galderma Laboratories, L.P. | $13.95 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Berman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.